IGC Pharma, Inc.
IGCStock
$0.26−21.11%52W
Market Cap$25.77M
P/E—
Div yield—
Beta0.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-22.34%
Price vs S&P 500 (4W)-4.09%
VGM Score35.51
Market Capitalization$25.77M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IGCIGC Pharma, Inc. | D | D | D | $0.26 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
IGC Pharma develops cannabinoid-based therapeutics for neurological and pain disorders. The company's Alzheimer's disease program includes four investigational candidates (IGC-AD1, IGC-M3, IGC-1C, and TGR-63) that have demonstrated preclinical potential to reduce amyloid plaques and tau tangles. Additional pipeline programs target period cramps, premenstrual syndrome, and chronic pain.